TheranosticTrials.org

Clinical Trial · NCT05392205

Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer

Overview

To evaluate the potential usefulness of 68Ga-FAP-2286 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, and compared with 18F-FDG PET/CT.

Sponsor

The First Affiliated Hospital of Xiamen University

Phase

N/A

Contacts

Long Sun, PhD (STUDY_DIRECTOR)

ClinicalTrials.gov

NCT05392205

Drug / Compound

FAP-2286

Isotope(s):
Target(s):
  • FAP
Ligand Class: Peptides
Chelator: DOTA
Linker: 1,3,5-benzenetrimethanethiol group

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • patients who had scheduled both 18F-FDG and 68Ga-FAP-2286 PET/CT scans;
  • patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report);

Exclusion

  • patients with pregnancy;
  • patients with non-malignant lesions;